

Table 3 continued

	I consult a reproductive specialist with questions about fertility issues in my patients				I refer patients who have questions about fertility to reproductive specialists			
	<i>p</i>	OR	95% CI		<i>p</i>	OR	95% CI	
			Min	Max			Min	Max
Knowledge								
Fair	0.442				0.162			
Not fair								
Attitude								
Conservative	0.032	1.000			0.003	1.656	1.183	2.319
Aggressive		1.599	1.014	2.798		1.000		
Gender								
Female	0.039	1.121	0.995	1.277	0.001	1.176	1.062	1.302
Male		1.000				1.000		
Age								
<50	0.264				0.004	1.424	1.110	1.828
>50						1.000		
Specialty								
Surgery	1.000				0.795			
Others								
Affiliation								
University hospital/cancer center	0.007	1.349	1.067	1.706	0.012	1.243	1.047	1.474
General hospital/private hospital						1.000		
Female physician colleague								
Present	0.051	1.467	0.995	2.164	0.123			
Absent		1.000						
Medical oncologist colleague								
Present	0.103				0.042	1.212	1.011	1.453
Absent						1.000		
Breast cancer-specialized nurse								
Present	0.710				1.000			
Absent								
Board-certified cancer pharmacist								
Present	0.803				0.138			
Absent								
Number of breast surgeries per week								
1–5	0.785				1.000			
6–								
Number of young patients per week								
0–1	0.270				0.813			
2–								
Partner/spouse								
Present	0.807				0.670			
Absent								
Children								
Present	0.197				0.209			
Absent								

of reproductive specialists or infertility clinic for referral (38%) were the major causes for them not to discuss fertility with patients.

Discussion

This study describes the attitude of the main providers of breast cancer treatment in Japan towards fertility issues in young breast cancer patients. The high response rate to our survey in a relatively short time indicates the interest of breast oncologists in fertility issues. More than 80% of the participants responded that they had a positive attitude when discussing fertility issues in the clinic, but this result may be biased by the respondents' interest in fertility issues. The recent awareness of fertility issues among Japanese breast oncologists may be related to the publication of the ASCO guideline in 2006 and the inclusion of fertility-related contents in JBCS patient guideline 2009 [2, 9]. Indeed, the JBCS treatment guideline, the standard textbook for board certification of Breast Oncologists, updated its contents to cover fertility-related issues in July 2010 [10].

The physicians with a positive attitude and working in institutions with medical oncologists and/or female colleagues had a higher likelihood of consultation or referral to reproductive specialists. The likelihood of referring to reproductive specialists was slightly higher in female physicians, which was consistent with the results of the survey in the USA [4]. These results indicate that participation of female healthcare providers in the team and a multidisciplinary working environment might enhance physicians' awareness of and behavior toward fertility-related issues. Because knowledge and attitude seem to be influenced by gender, personal experience, and the working environment of the physicians, we think that outreach with educational materials and systematic learning opportunities for healthcare providers would be helpful in expanding knowledge and performance regarding fertility issues in young breast cancer patients.

High risk of disease recurrence was considered the greatest barrier for physicians, similar to the results of other studies [5, 6]. In our previous study, patients' with higher risk of disease recurrence did not voluntarily express their concerns regarding fertility when compared to patients of lower risk of disease recurrence [3]. Both patients and physicians may refrain from discussing future fertility when the estimation of prognosis of the cancer is poor. Although early referral to reproductive specialists might increase the patients' likelihood of receiving reproductive intervention and improve the fertility outcome [11, 12], fertility preservation techniques such as embryo preservation and oocyte preservation connote ethical issues especially in patients with poor prognosis [13]. Ethical and

psychosocial support is necessary in the shared decision-making process among patients, families, and physicians.

A lack of reproductive specialists or infertility clinic for referral is a real problem. A survey in the USA showed that many breast cancer clinicians reported that they do not have knowledge of or resources for fertility preservation [8, 14]. Interdisciplinary communication between reproductive specialists and oncologists is necessary.

Early case-control studies suggest that pregnancy after primary treatment of breast cancer does not have a negative impact on cancer prognosis, although "healthy mother" bias might exist [15]. Because prognostication of breast cancer has become individualized using genetic biomarkers [16, 17], further investigations to clarify the impact of pregnancy after primary treatment on an individual basis is needed so that patients can personalize their decision-making regarding both cancer treatment and fertility.

In conclusion, Japanese breast oncologists were in general positive in discussing fertility issues with young breast cancer patients. Female and younger physicians as well as physicians working in a multidisciplinary environment had more positive attitudes and behavior towards fertility preservation. The development of multidisciplinary and interdisciplinary programs is necessary to meet the fertility needs of breast cancer patients.

Acknowledgments This study was supported by the Ministry of Health, Science and Welfare, Grant-in-Aid for Clinical Research in Cancer (H21-021). There were no financial disclosures from any authors. We thank Professor Richard Theriault of the University of Texas M. D. Anderson Cancer Center for his editorial assistance in preparing this manuscript.

References

1. Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. *Psychooncology*. 2010 (Epub ahead of print).
2. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol*. 2006;24(29):17–2931.
3. Kubo A, Koido K, Sawada M, Ryushima Y, Shimizu C, Kato T, Ando M, et al. Survey on oncologists provided information on treatment-related infertility to breast cancer patients. *Gan to Kagakuryoho (Cancer Chemother)*. 2011 (in press).
4. Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Belper G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. *J Clin Oncol*. 2009;27:5952–7.
5. Arafa MA, Rabah DM. Attitudes and practices of oncologists toward fertility preservation. *J Pediatr Hematol Oncol*. 2011;33:203–7.
6. Collins IM, Fay L, Kennedy MJ. Strategies for fertility preservation after chemotherapy: awareness among Irish cancer specialists. *Ir Med J*. 2011;104:6–9.
7. Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It's now or never: fertility-related knowledge,

- decision-making preferences, and treatment intentions in young women with breast cancer—an Australian Fertility Decision Aide Collaborative Group Study. *J Clin Oncol*. 2011 (Epub ahead of print).
8. Quinn GP, Vadaparamil ST, King L, Miree CA, Wilson C, Raj O, et al. Impact of physicians' personal discomfort and patient prognosis on discussion of fertility preservation with young cancer patients. *Patient Educ Couns*. 2009;77:338–43.
 9. Japanese Breast Cancer Society. Breast cancer treatment guideline for patients 2009. Tokyo: Kanehara Shoten; 2010 (Japanese).
 10. Japanese Breast Cancer Society. Breast cancer treatment guideline 2010. Tokyo: Kanehara Shoten; 2010 (Japanese).
 11. Lee S, Heytens E, Moy F, Ozkavukcu S, Otkay K. Determinants of access to fertility preservation in women with breast cancer. *Fertil Steril*. 2011;95:1932–6.
 12. Lee S, Ozkavukcu S, Heytens E, Moy F, Otkay K. Value of early referral to fertility preservation in young women with breast cancer. *J Clin Oncol*. 2010;28:4683–6.
 13. Gerber B, Dieterich M, Muller H, Remer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. *Breast Cancer Res Treat*. 2008;108:1–8.
 14. Goldfarb S, Dickler M, McCabe M, Thom B, Jia X, Hudis C, et al. Oncology clinicians knowledge, attitude and practices regarding fertility preservation. *J Clin Oncol*. 2010;28(15 Suppl): e19525.
 15. Kranick MA, Schaefer C, Rowell S, Desai M, Petrek JA, Hiatt RA, Senie RT. Is pregnancy after breast cancer safe? *Breast J*. 2010;16:404–11.
 16. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. *Nat Rev Clin Oncol*. 2010; 7:725–32.
 17. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel Members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. *Ann Oncol*. 2009;20:1319–29.

Quantitative assessment of appearance changes and related distress in cancer patients

Keiko Nozawa^{1,2}, Chikako Shimizu^{3*}, Minako Kakimoto³, Yuri Mizota⁴, Seiichiro Yamamoto⁴, Yumiko Takahashi⁵, Atsuko Ito⁵, Hideko Izumi⁵ and Yasuhiro Fujiwara³

¹Yamano College of Aesthetics, Tokyo, Japan

²Cancer Information and Support Center, National Cancer Center Hospital, Tokyo, Japan

³Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

⁴Center for Cancer Control and Information, National Cancer Center, Tokyo, Japan

⁵Department of Nursing, National Cancer Center Hospital, Tokyo, Japan

*Correspondence to:

Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: cshimizu@ncc.go.jp

Abstract

Objectives: This study examined both the frequency of appearance-related symptoms and distress resulting from these symptoms in cancer patients receiving chemotherapy.

Methods: Self-report questionnaires were distributed to 753 outpatients receiving ≥ 4 weeks of treatment at an outpatient chemotherapy center. Valid responses were returned by 638 patients (response rate, 84.7%). Participants were questioned about 57 appearance-related symptoms (AS) and 23 non-appearance-related physical symptoms (non-AS); psychological well-being was assessed using a shortened version of the Derriford Appearance Scale 59.

Results: Questionnaire responses were obtained from 264 male and 374 female patients (mean age, 59.5 years; range, 18–85 years). Most respondents (80.3%) were concerned with changes in appearance resulting from treatment. By sex and disease type, women suffered more than men, and treatment for breast cancer created the greatest distress for women.

Conclusion: Cancer patients are concerned about a variety of AS, and these may result in greater distress than non-AS. AS-related information and care are increasingly being sought in advance of treatment. Copyright © 2013 John Wiley & Sons, Ltd.

Received: 10 January 2012

Revised: 30 October 2012

Accepted: 28 January 2013

Introduction

Patient distress is an important factor that impacts greatly on quality of life, psychological well-being (PWB), and treatment decisions and outcomes [1–4]. Advances in medical technology – such as the development of antiemetic drugs and other new medications [5,6] – have led to reductions in distress from the physical symptoms that accompany cancer treatment. However, increases in distress from symptoms of psychosocial origin were pointed out as early as the 1990s [7,8]. This may be attributable to the greater number of patients who now undergo shorter periods of hospitalization [9] and/or continue to lead active lives even while undergoing treatment, thanks to advances in outpatient care therapies and facilities. Patients are thus now more likely to be aware of treatment-related changes in appearance and suffer distress as a result [10–12]. Accordingly, changes in appearance can be considered an important element of distress.

However, with the exception of studies examining such localized treatment-related side effects as scalp alopecia and mastectomy [13–18], little detailed quantitative research has focused on treatment-related changes in appearance as a whole [17,19], and few studies have investigated the impact of cancer type, age, and sex on these appearance problems [10,20].

Accordingly, the present study aimed to elucidate the incidence of appearance changes and the degree of distress due to such changes associated with cancer treatments.

Patients were stratified on the basis of disease and sex and compared in terms of distress experienced because

of appearance-related (AS) and non-appearance-related physical symptoms (non-AS). We were thus able to more clearly elucidate the characteristics of distress due to AS.

We investigated dependent variables on the basis of the following two hypotheses. First, with regard to sex, the body awareness of men is considered more likely to focus on functional capabilities, whereas that of women is more likely to focus on appearance [21–23]. The degree of appearance-related distress could thus be expected to differ according to sex, with women experiencing greater distress than men (Hypothesis 1). Second, with regard to age, younger patients may be more likely to focus on appearance than older patients [24]. Younger patients could thus be expected to experience greater levels of distress due to AS (Hypothesis 2).

Methods

Participants

All study participants received chemotherapy on an outpatient basis at the National Cancer Center Hospital (NCCCH) in Tokyo between July and October 2009. At the time of distribution of the self-report questionnaire, all participants satisfied the following inclusion criteria: (1) performance status 0–2; (2) age ≥ 18 years; and (3) completion of ≥ 4 weeks of chemotherapy as calculated from the time of the initial treatment session.

Procedures

During the study period, a list of potential participants was created by continuous sampling of eligible patients

undergoing anticancer therapy at the Outpatient Treatment Center of NCCCH. From that list, self-report questionnaires were distributed to 753 patients who signed an informed consent form. Of these, 638 patients returned valid responses by mail (response rate, 84.7%). For each participant, the site of cancer and the chemotherapeutic agents used for treatment were confirmed through the use of electronic medical charts. The study protocol was approved by the institutional review board of the NCCCH. Study participants included 202 gastrointestinal cancer patients, 175 breast cancer patients, 69 hepatobiliary/pancreatic cancer patients, 60 hematological cancer patients, 55 lung cancer patients, and 77 patients with other types of cancer.

Measures

The questionnaire was designed to elicit information on the demographic and medical variables of participants, along with the frequency and degree of distress due to non-AS, such as nausea and constipation, and AS, such as hair loss, the presence or absence of concern regarding changes in appearance, and the impact of appearance issues on PWB.

Non-appearance-related symptoms

Griffin *et al.* [7] used 45 comprehensive items in a study evaluating the distress associated with chemotherapy-induced symptoms. For the present questionnaire, we initially selected those 29 items experienced by $\geq 20\%$ of the participants in the study by Griffin *et al.* After eliminating six AS, we arrived at a total of 23 non-AS items.

(1) With regard to the presence/absence of symptoms, each patient was asked which symptoms they (a) had experienced in the past; (b) were currently experiencing; and (c) had never experienced. If a respondent had experienced a symptom in the past and was also experiencing the same symptom in the present, both responses were checked. (2) Patients were asked to rate the degree of distress using a 4-point scale: 1 (*none*); 2 (*mild*); 3 (*moderate*); and 4 (*severe*). As feelings of wellness are constantly changing, participants were asked to base the assessment of an item on the level of distress perceived at the time of most intense distress. The Japanese translation of the non-AS items from the study by Griffin *et al.* that appeared in our questionnaire, as well as a check of the accuracy of that translation, was prepared after much deliberation by two oncologists and a dermatologist.

In addition, with regard to the total degree of distress due to non-AS, the total points for the items currently being experienced were used as an index (total score calculated using 0 as the score for the degree of distress due to side effects not experienced). This score showed a high internal consistency in this sample ($\alpha = 0.89$).

Appearance-related symptoms

As for the AS items included in our questionnaire, because no previous studies, including that by Griffin *et al.*, have attempted to examine such a wide range of AS in a systematic, comprehensive manner, we decided to supplement eight AS items chosen from the study by Griffin *et al.* with other items derived from interviews with

medical staff. Ultimately, 57 items were selected, including 40 chemotherapy-induced items, 14 items resulting from surgical treatment, and three radiation therapy-induced items. The items were then checked and reviewed by two oncologists, along with five oncology nurses from NCCCH. In addition, to confirm the validity of the previously mentioned items, a pilot study [25] was conducted on 102 cancer patients with the same cancer tumor-type distribution as the main study participants.

In the pilot study, all 57 items were experienced by at least one patient, whereas there were no entries indicating other symptoms in a 'Comments' column that had been added on an exploratory basis. We thus surmised that the selected items were sufficiently comprehensive.

Using the same method as for non-AS, we inquired the (1) presence or absence of experience of each symptom and (2) degree of distress for each item, and also calculated the total for the degree of distress due to AS. In this sample, as well, this score showed a high internal consistency ($\alpha = 0.92$).

Table 1. Demographic of respondents of the study population ($n = 638$)

	n	%
Age, years		
59.5 ± 11.7 years (mean)		
Gender		
Female	264	58.6
Male	374	41.4
Employment status		
Employed	251	39.4
Unemployed, retired	387	60.6
Marital status		
Married or de facto	492	77.1
Single	49	7.7
Divorced, widowed, or separated	82	12.9
Unknown	15	2.4
Type of cancer		
Gastrointestinal	202	31.7
Breast	175	27.4
Hepatobiliary	69	10.8
Hematological	60	9.4
Lung	55	8.6
Other	77	12.1
Extent of disease		
Local	363	56.9
Metastatic	275	43.1
Months from first chemotherapy		
6.7 ± 8.5 months (mean), range: 0.9–65.4 months		
Other treatments		
Surgical therapy	378	59.4
Radiation therapy	72	11.3
Hormone therapy	17	2.7
Medication		
Taxane	140	21.9
Anthracycline	98	15.4
Platinum	141	22.1
Antimetabolite	276	43.3
Alkylating	93	14.6
Molecular target	202	31.7
Other	134	21.0
Days of external activities per week		
Less than 1 day	246	38.6
3 days	180	28.2
5 days	95	14.9
Every day	117	18.3
Prevalence of concern about appearance changes by gender		
Female	324	86.6
Male	188	71.2

Table 2. Non-appearance-related symptom frequency and distress by gender and cancer type

	Gastrointestinal cancer			Breast cancer		Hepatobiliary/pancreatic cancer			Hematological cancer			Lung cancer		
	Patients reporting symptom	Mean degree of distress		Patients reporting symptom	Mean degree of distress	Patients reporting symptom	Mean degree of distress		Patients reporting symptom	Mean degree of distress		Patients reporting symptom	Mean degree of distress	
		Male (134)	Female (68)		Female (174)		Male (36)	Female (33)		Male (28)	Female (32)		Male (29)	Female (26)
%			%		%			%			%			
Nausea and emesis	68.3	2.48	2.83	74.3	3.14	66.7	2.33	2.28	63.3	3.06	3.35	72.7	2.75	2.80
Fatigue	80.2	2.14	2.64	90.3	2.71	76.8	2.19	2.32	88.3	2.74	3.12	80.0	2.35	2.73
Dizziness	49.5	1.77	2.24	52.0	2.10	50.7	2.00	2.00	56.7	2.25	2.83	58.2	1.88	2.29
Shortness of breath	49.0	1.95	2.55	60.6	2.24	44.9	1.80	2.07	63.3	2.12	2.90	72.7	2.42	2.32
Tinnitus	24.3	1.68	2.05	30.9	1.88	20.3	1.64	2.00	30.0	1.67	2.25	36.4	2.00	1.69
Hot flashes	27.7	1.67	2.17	54.9	2.30	24.6	1.73	1.62	41.7	2.20	2.31	25.5	1.71	2.33
Dry mouth	44.6	1.51	1.91	52.6	1.90	42.0	1.53	1.71	50.0	2.20	2.62	40.0	1.62	2.00
Oral mucositis	64.4	2.33	2.79	71.4	2.70	34.8	1.92	1.92	65.0	2.95	2.63	45.5	2.54	2.45
Taste disturbance	70.8	2.26	2.63	74.9	2.61	55.1	2.05	2.27	68.3	2.37	3.14	70.9	2.32	2.79
Dysosmia	32.7	1.79	2.52	40.6	2.46	43.5	2.00	2.07	38.3	2.27	3.18	43.6	2.50	2.67
Weight changes	70.8	1.64	2.29	63.4	1.83	75.4	1.45	2.00	70.0	2.19	2.09	67.3	1.78	1.59
Appetite changes	76.2	2.27	2.47	69.1	2.21	66.7	2.08	2.35	71.7	2.28	2.70	67.3	2.25	2.27
Constipation	67.8	2.30	2.81	74.3	2.75	63.8	2.63	2.14	73.3	2.44	2.78	70.9	2.20	3.06
Diarrhea	68.3	2.34	2.85	54.3	2.40	55.1	2.29	2.72	45.0	2.27	2.19	50.9	2.33	2.00
Frequent urination	44.6	1.95	2.17	53.7	1.82	43.5	1.67	2.24	55.0	1.80	2.11	47.3	1.77	1.80
Irregular menstruation	10.9	—	1.57	42.0	1.67	13.0	—	1.67	23.3	—	2.50	23.6	—	1.25
Insomnia	50.5	2.00	2.73	62.9	2.28	44.9	2.14	2.28	61.7	2.56	2.53	60.0	2.35	2.46
Pruritus	44.6	2.09	2.48	49.7	2.37	46.4	2.42	2.32	41.7	2.08	2.55	58.2	1.93	2.50
General pain	13.9	2.50	3.10	42.9	2.82	18.8	2.00	2.38	31.7	2.50	3.11	40.0	2.80	3.10
Headaches	28.2	2.04	2.22	51.4	2.55	36.2	2.23	2.30	41.7	2.70	3.08	25.5	2.40	2.57
Treatment site pain	29.7	2.29	2.50	64.0	2.41	44.9	2.15	2.00	40.0	2.44	2.85	29.1	2.14	2.00
Sensory neuropathy	71.3	2.32	2.88	65.1	2.84	37.7	2.25	2.67	76.7	2.55	3.12	65.5	2.50	2.92
Fever	28.7	2.17	2.87	53.1	2.70	36.2	2.25	2.20	50.0	2.79	2.46	30.9	2.44	2.62

Table 3. Appearance-related symptom frequency and distress by gender and cancer type

Symptom	Gastrointestinal cancer			Breast cancer		Hepatobiliary cancer			Hematological cancer			Lung cancer			
	Patients reporting symptom	Mean degree of distress		Patients reporting symptom	Mean degree of distress	Patients reporting symptom	Mean degree of distress		Patients reporting symptom	Mean degree of distress		Patients reporting symptom	Mean degree of distress		
		%	Male (134)				Female (68)	%		Female (174)	%		Male (36)	Female (33)	%
Chemotherapy induced															
Scalp hair loss	73.8	2.12	2.78	96.0	3.47	39.1	1.80	2.26	95.0	2.23	3.44	90.9	2.17	3.17	
Loss of eyebrows	39.1	1.85	2.30	80.6	2.77	8.7	1.00	2.14	43.3	1.38	3.00	67.3	2.06	2.61	
Loss of eyelashes	29.7	1.74	2.65	74.9	2.76	2.9	1.00	2.33	35.0	1.88	2.73	58.2	2.00	2.58	
Loss of vibrissae	21.8	1.59	1.87	64.0	2.16	4.3	1.00	1.50	31.7	1.00	2.12	45.5	1.79	1.82	
Lip desquamation	16.3	2.09	2.28	26.9	2.12	13.0	2.00	1.50	30.0	1.80	2.18	18.2	1.00	1.89	
Facial discoloration	33.2	1.81	2.82	35.4	2.56	26.1	1.75	2.56	28.3	1.60	2.69	21.8	1.00	2.50	
Skin blemishes, under-eye circles	39.1	1.73	2.64	51.4	2.57	27.5	2.00	2.45	36.7	1.67	2.50	23.6	1.80	2.17	
Facial dry skin	18.3	2.00	2.44	41.1	2.22	11.6	1.00	2.33	25.0	1.71	2.38	23.6	1.50	2.17	
Facial edema	30.7	2.18	2.67	53.7	2.58	26.1	2.43	2.00	36.7	2.62	2.58	36.4	1.71	2.30	
Hoarseness	19.3	1.74	2.50	10.3	2.38	2.9	—	2.00	20.0	2.25	3.00	20.0	2.62	—	
CV-port	56.4	1.49	2.28	15.4	1.87	8.7	1.25	2.00	6.7	2.33	4.00	3.6	1.00	—	
Weight gain	28.7	1.64	1.88	44.0	2.18	18.8	3.00	2.12	13.3	2.33	3.00	27.3	1.71	2.60	
Weight loss	56.9	1.63	2.00	44.0	1.42	59.4	1.48	2.28	49.2	1.78	1.95	60.0	1.71	1.54	
Fingernail discoloration	49.5	1.69	2.15	80.0	2.39	14.5	1.00	1.50	46.7	1.62	2.47	45.5	1.50	2.29	
Transverse furrows on fingernails	38.6	1.57	2.10	68.0	2.29	14.5	1.33	1.50	35.0	1.33	2.38	45.5	1.55	2.23	
Split fingernails	37.6	1.95	2.62	46.3	2.75	21.7	1.75	1.67	18.3	1.83	2.00	29.1	2.00	2.75	
Fingernail onycholysis	9.9	2.00	2.17	33.1	2.75	4.3	1.00	1.00	10.0	2.00	2.00	18.2	1.67	2.57	
Fingernail detachment	12.9	2.07	2.55	31.4	2.61	2.9	2.00	2.00	8.3	1.75	3.00	18.2	2.00	2.40	
Hair loss on hands	18.8	1.28	1.57	42.3	1.17	4.3	1.00	2.00	23.3	1.00	1.13	29.1	1.55	1.00	
Hand discoloration	38.6	1.67	2.48	29.1	2.48	26.1	1.57	2.00	21.7	1.67	2.90	16.4	1.50	2.25	
Dry skin of hands	22.8	1.96	2.05	35.4	1.95	15.9	1.50	2.00	18.3	1.71	2.67	16.4	1.67	2.50	
Desquamation of hands	24.3	2.08	2.50	20.0	2.33	8.7	1.00	2.50	13.3	1.33	2.80	16.4	1.60	2.25	
Hand edema (lymphedema)	14.9	1.69	2.53	37.1	2.49	10.1	2.25	2.33	20.0	2.29	2.60	21.8	1.67	2.38	
Upper limb hair loss	22.8	1.19	1.30	52.0	1.09	1.4	1.00	1.00	26.7	1.00	1.00	34.5	1.42	1.00	
Discoloration of upper limbs	10.4	1.44	2.27	14.3	1.91	8.7	2.00	1.80	15.0	1.67	3.33	7.3	2.00	2.50	
Dry skin of upper limbs	13.9	1.50	2.00	21.7	1.77	5.8	3.00	2.00	16.7	1.75	2.33	7.3	1.50	2.50	
Injection site scar on arms	27.7	1.38	2.05	58.9	2.19	36.2	2.09	2.38	35.0	2.20	2.79	32.7	1.67	2.25	
Upper limb edema	3.0	1.33	3.50	35.4	2.53	2.9	—	1.50	6.7	3.00	3.00	9.1	1.00	2.50	
Toenail discoloration	43.1	1.50	2.13	71.4	2.06	10.1	3.00	1.57	33.3	1.67	2.36	43.6	1.25	1.86	
Transverse furrows on toenails	25.2	1.62	2.05	49.1	2.14	10.1	2.00	1.50	25.0	1.22	2.50	36.4	1.33	2.22	
Split toenails	20.8	1.93	2.36	31.4	2.37	8.7	2.50	1.25	11.7	1.50	3.00	16.4	1.75	2.25	
Toenail onycholysis	5.4	1.67	1.75	23.4	2.42	2.9	—	1.00	1.7	2.00	—	7.3	—	2.67	
Toenail detachment	9.9	2.18	2.50	29.1	2.71	2.9	2.00	1.00	3.3	2.00	—	7.3	1.67	3.00	
Lower limb hair loss	26.7	1.18	1.18	57.7	1.09	4.3	1.50	—	35.0	1.08	1.13	45.5	1.40	1.13	
Foot discoloration	15.8	1.94	2.47	19.4	2.03	4.3	—	3.00	20.0	3.00	3.00	5.5	1.00	2.00	

Foot desquamation	20.8	2.00	1.84	18.3	2.00	8.7	2.00	2.25	10.0	1.50	2.00	10.9	1.60	2.00
Pedal edema	27.2	2.12	2.82	42.9	2.64	26.1	2.75	2.20	26.7	2.57	2.57	30.9	2.00	2.22
Vulnerable skin	24.3	2.04	2.08	30.3	2.27	17.4	1.50	1.83	28.3	2.57	2.44	14.5	1.67	2.00
Eczema	32.2	2.22	2.47	38.9	2.51	27.5	2.22	2.29	38.3	2.50	2.75	32.7	2.12	2.33
Surgical therapy induced scars on the body surface	58.9	1.48	2.02	68.0	2.76	49.3	1.70	2.67	15.0	1.50	2.80	18.2	1.60	2.00
Mastectomy	0.5	—	1.17	64.6	3.22	4.3	—	2.60	3.3	—	4.00	5.5	—	1.50
Tubes outside of the body, indwelling tubes	14.4	2.07	2.62	25.1	2.22	26.1	2.29	1.90	10.0	3.50	2.75	9.1	3.00	3.00
Stoma	14.9	2.60	3.00	0.6	1.00	2.9	—	3.50	1.7	—	1.00	1.8	2.00	—
Radiation therapy induced dermatitis and ulcers	3.5	1.60	—	28.0	2.24	0.0	—	—	3.3	3.00	1.00	5.5	2.00	3.00

Other (frequency rate < 15%).
 Surgical therapy induced: 10 items.
 Radiation therapy induced: two items.
 Additional cited symptoms: seven items.

Appearance changes and psychological well-being

Unlike physical symptoms such as nausea, appearance changes such as scalp alopecia can not only cause physical distress but also exert a considerable negative impact on mental health as a result of decreased self-esteem and the fear of being deemed unattractive by others. We used a 12-item Japanese version [26] of the Derriford Appearance Scale 59 (DAS-59) [27–29] to measure psychological distress and behavioral impairment in patients concerned with problems of appearance in both clinical and non-clinical populations. This 12-item DAS-derived scale comprised three items selected from each of four DAS-59 factors. With a maximum score of 56 and a minimum score of 0, higher scores on this scale indicated lower levels of PWB in patients with appearance-related concerns.

The 12 items showed a high degree of one-dimensionality in this sample ($\alpha=0.92$). It was thus concluded that this approach offers a reliable and valid tool.

Statistical analysis

The sociodemographic variables of the study population, cancer types, and the treatment received for the said cancers were specified (Table 1). The frequency and mean degree of distress were tabulated for each AS and non-AS item by both cancer type and sex.

Tables 2 and 3 compile the data for symptom frequencies (percentage of patients reporting symptoms) and mean degree of distress for non-AS and AS. Table 4 lists the 20 most distressful symptoms by sex for gastrointestinal and breast cancer patients. For AS, the difference in total distress scores between men and women was tested using the *t*-test, whereas differences between diseases were tested by one-way analysis of variance. Correlation analysis was also performed to elucidate relationships to variables such as age (Table 5).

Results

Survey response

A significant number of female participants in the 638-participant study population reported being ‘concerned about some aspect of appearance’ ($\chi^2(1)=23.22, p < 0.01$) (Table 1). A *t*-test analysis demonstrated no difference between mean ages of female and male participants by cancer type.

Frequency and degree of distress from non-appearance-related symptoms

There were also many non-AS, which were experienced by more than 60% of patients. Of the non-AS reported, the most frequently cited (76.8–90.3%) was ‘fatigue’ (Table 2).

Analysis of differences between the sexes in total degree of distress scores for non-AS associated with each disease revealed no significant differences other than for gastrointestinal cancer (men, 21.11 ± 12.69 ; women, 28.75 ± 15.04 ; $t(200) = 3.79$; $p < 0.00$).

Frequency and degree of distress from appearance-related symptoms

Table 3 shows the frequency and mean degree of distress for each AS by both sex and cancer type. Items with a

Table 4. Twenty most distressful symptoms of chemotherapy by gender

Rank	Gastrointestinal		Breast
	Male (n = 134)	Female (n = 68)	Female (n = 174)
	Symptom	Symptom	Symptom
1	Stoma ^a	Stoma ^a	Scalp hair loss ^a
2	Nausea and emesis	Sensory neuropathy	Removal of a breast ^a
3	Diarrhea	Fever	Nausea and emesis
4	Oral mucositis	Diarrhea	Sensory neuropathy
5	Sensory neuropathy	Nausea and emesis	General pain
6	Constipation	Facial discoloration ^a	Loss of eyebrows ^a
7	Treatment site pain	Pedal edema ^a	Loss of eyelashes ^a
8	Appetite changes	Constipation	Scars on the body surface ^a
9	Taste disturbance	Oral mucositis	Constipation ^a
10	Eczema ^a	Scalp hair loss ^a	Split fingernails ^a
11	Facial edema ^a	Insomnia	Fingernail onycholysis
12	Fever	Facial edema ^a	Fatigue ^a
13	Fatigue	Loss of eyelashes ^a	Toenail detachment
14	Scalp hair loss ^a	Skin blemishes, Under-eye circles ^a	Oral mucositis
15	Pedal edema ^a	Fatigue	Fever
16	Lip desquamation ^a	Taste disturbance	Pedal edema ^a
17	Pruritus	Split fingernails ^a	Taste disturbance ^a
18	Hand discolorations ^a	Shortness of breath	Loss of fingernails
19	Scratch easily ^a	Hand edema (lymphedema) ^a	Facial edema ^a
20	Headaches	Dysosmia	Skin blemishes, under-eye circles ^a

^aAppearance-related symptom

Table 5. Correlations between degree of appearance-related symptom

	Gastrointestinal		Breast	Hepatobiliary		Hematological		Lung	
	Male	Female	Female	Male	Female	Male	Female	Male	Female
DAS	0.26***	0.32***	0.22***		0.64***		0.33*	0.56***	
Age		-0.39***				-0.33*			-0.34*

* $p > 0.10$,

** $p > 0.05$,

*** $p > 0.01$.

≥15% frequency for at least one cancer type are presented in this table. Although the frequency of AS occurrence differed according to cancer type, virtually no part of the body was not associated with some type of AS.

For each disease, the 20 most distressful symptoms occurring at a frequency of ≥15% were compared for sex differences in the degree of distress. Table 4 shows data for gastrointestinal cancers and breast cancer, which accounted for the largest number of patients in the sample. Comparison of the sex differences in total distress score due to appearance changes associated with each disease found that women experienced significantly greater distress than men for each of the analyzed diseases except for hematological cancer: gastrointestinal (men, 17.09 ± 13.58 ; women, 31.63 ± 19.84 ; $t(200) = 6.12$; $p < 0.00$), hepatobiliary/pancreatic (men, 9.14 ± 8.57 ; women, 16.30 ± 14.62 ; $t(67) = 2.58$; $p = 0.02$) and lung (men, 16.66 ± 13.28 ; women, 26.46 ± 15.61 ; $t(53) = 2.52$; $p = 0.02$).

Differences among diseases were also tested for significance. Because breast cancer was limited to women, single-factor analysis of variance was performed using the disease, and sex was handled as an independent variable, whereas total distress score relating to appearance was considered a dependent variable. The results revealed a significant difference as a function of group ($F(8, 551) = 23.87$; $p < 0.00$). Multiple comparisons performed using Tukey's method showed the breast cancer (female)

group had experienced a significantly higher degree of stress due to changes in appearance compared with all other groups. Data for each group were as follows: gastrointestinal cancer male (17.09 ± 13.58); gastrointestinal cancer female (31.63 ± 19.84); breast cancer female (41.02 ± 24.79); hepatobiliary/pancreatic cancer male (9.14 ± 8.57); hepatobiliary/pancreatic cancer female (16.30 ± 14.62); hematological cancer male (17.68 ± 17.23); hematological cancer female (26.00 ± 21.92); lung cancer male (16.66 ± 13.28); and lung cancer female (24.46 ± 21.94).

Correlation with degree of distress from appearance-related symptoms

Correlation analysis was performed for the degree of distress due to changes in appearance and age and DAS scores. Table 5 shows that degree of distress correlated negatively with age but positively with DAS score.

Discussion

There were as many as 80% of cancer patients concerned about changes in appearance arising as a result of therapy. In fact, although differences were seen as a function of the type of cancer and the sex of the patient, changes in appearance occurred broadly throughout the body as a

Appearance changes in cancer patients

whole, and in some cases, the distress associated with them was greater than that for non-AS such as fever.

In most patients, total distress score for AS showed a difference by sex in comparison with non-AS. That is, women felt greater distress than men with regard to symptoms that affected their appearance. The results also indicated differences in the causes of distress in patients. As exemplified by the case of gastrointestinal cancer, the highest ranked 20 items for male participants were primarily non-AS. The AS that appeared on the top 20 list were largely symptoms that impacted physical function, such as pedal edema that rendered walking more difficult. Female participants were more aware of appearance [21,22]. Distress related to hair loss, for example, was felt more strongly by female participants. Similarly, although not causing physical pain or itching, visible symptoms such as eyelash loss and facial discoloration were often ranked higher than typical non-AS. No distress was associated with lower limb hair loss. The greater distress experienced by female participants relative to AS may be an extension of a greater awareness and concern seen in women, in general, relative to beauty and cosmetic [30–32]. In the comparison of the diseases, this was especially true for the group of female patients with breast cancer. This finding supports Hypothesis 1.

The greater the distress due to AS, the higher the DAS score, while PWB decreased. With regard to patient age,

the study results supported Hypothesis 2, not for all disease types but for women with gastrointestinal cancer, men with hematological cancer, and women with lung cancer.

This study had certain limitations. The sample was limited to patients in a single cancer treatment center in a major urban area. Future research should be undertaken to expand the number and geographical diversity of treatment centers.

In conclusion, as the frequency of symptoms and the degree of distress associated with AS are quite high, hospitals need to start providing information and care related to appearance [33–35].

This study quantitatively elucidated high-priority items, attributes, and diseases, and the results will be able to serve as basic data for the development of support programs focused on symptoms representing the source of great distress to cancer patients.

Acknowledgements

We thank the staff of the Outpatient Treatment Center. This study was supported by a grant from the Grants-in-Aid for Scientific Research, Basic Research C program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (2009–2010), as well as a grant from the Grant-in-Aid for Clinical Research in Cancer program of the Japanese Ministry of Health, Science and Welfare (H21-021) (2009–2011).

References

1. Sutherland HJ, Llewellyn-Thomas HA, Lockwood GA, Trichter DL, Till JE. Cancer patients: their desire for information and participation in treatment decisions. *J R Soc Med* 1989;**82**:260–263.
2. Elkin EB, Kim SH, Casper ES, Kissanc DW, Schrag D. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. *J Clin Oncol* 2007;**25**:5275–5280.
3. Romanek KM, McCaul KD, Sandgren AK. Age differences in treatment decision making for breast cancer in a sample of healthy women: the effects of body image and risk framing. *Oncol Nurs Forum*. 2005;**1**(32):799–806.
4. Benbassat J, Pilpel D, Tidhar M. Patients' preferences for participation in clinical decision making: a review of published surveys. *Behav Med* 1998; **24**(2):81–88.
5. Chevallier B. The control of acute cisplatin-induced emesis – a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. *Br J Cancer* 1993;**68**:176–180.
6. Naeim A, Dy SM, Lorenz KA, Sanati H, Walling A, Asch SM I. Evidence-based recommendations for cancer nausea and vomiting. *J Clin Oncol* 2008;**26**:3903–3910.
7. Griffin AM, Butow PN, Coates AS, Ellis PM, Dunn SM, Tattersall MH. On the receiving end V. Patient perceptions of the side effects of cancer chemotherapy in 1993. *Ann Oncol* 1996;**7**:189–195.
8. Coates AS, Abraham S, Kaye SB, Souerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end: patient perception of the side effects of chemotherapy. *Eur J Cancer Clin Oncol* 1983;**19**:203–8.
9. Downing A, Lansdown M, West RM, Thomas JD, Lawrence G, Forman D. Changes in and predictors of length of stay in hospital after surgery for breast cancer between 1997/98 and 2004/05 in two regions of England: a population-based study. *BMC Health Serv Res* 2009;**9**:202.
10. Flexen J, Ghazali N, Lowe D, Rogers SN. Identifying appearance-related concerns in routine follow-up clinics following treatment for oral and oropharyngeal cancer. *Br J Oral Maxillofac Surg* 2012;**50**:314–320.
11. Moreira H, Crespo C, Paredes T, Silva S, Canavarró MC, Dattilio FM. Marital relationship, body image and psychological quality of life among breast cancer patients: the moderating role of the disease's phases. *Contemporary Family Therapy* 2011;**33**:161–178.
12. Sharpe L, Patel D, Clarke S. The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. *J Psychosom Res* 2011;**70**:395–402.
13. Mcgarvey EL, Baum LD, Pinkertom RG, Rogers LM. Psychological sequelae and alopecia among women with cancer. *Cancer Pract*. 2001;**9**(6):283–289.
14. Batchelor D Hair and cancer chemotherapy: consequences and nursing care – a literature study. *Eur J Cancer Care* 2001;**10**:147–163.
15. Hesketh PJ, Batchelor D, Golant M, et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. *Support Care Cancer* 2004;**12**:543–549.
16. Waljee JF, Hu ES, Newman LA, Alderman AK. Correlates of patient satisfaction and provider trust after breast-conserving surgery. *Cancer* 2008;**112**:1679–1687.
17. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer. *Lit Rev*. 2008;**17**(4):317–28.
18. Schnur JB, Ouellette SC, DiLorenzo TA, Green S, Montgomery GH. A qualitative analysis of acute skin toxicity among breast cancer radiotherapy patients. *Psycho-Oncology* 2011;**20**:260–268.
19. Liu HE. Changes of satisfaction with appearance and working status for head and neck tumour patients. *J Clin Nurs* 2008;**17**:1930–1938.
20. Vilaseca I, Chen AY, Bacscheider AG. Long-term quality of life after total laryngectomy. *Head Neck* 2006;**28**(4):313–20.
21. Halliwell E, Dittmar H. A qualitative investigation of women's and men's body image concerns and their attitudes toward aging. *Sex Roles* 2003;**49**:675–684.
22. Leary MR. Understanding Social Anxiety: Social, Personality, and Clinical Perspectives. SAGE Publications: London, 1983.
23. Holdcroft AI, Berkley KJ. Sex and gender differences in pain and its relief. In Wall and Melzack's Textbook of Pain (5th edition) Churchill Livingstone: Philadelphia, 2005; 1181–1197.
24. Nabeta Y. Anthropophobia and dysmorphophobia. Kongo shuppan 1997; 205–208 (in Japanese)
25. Ito A, Shimizu C. Side-effects of cancer treatment and its impact on quality of life in oncology patients. *The 8th Annual Meeting of Japanese Society of Medical Oncology patients receiving cancer chemotherapy* 2010; 269 (in Japanese)
26. Nozawa K, Konno H. Reliability and validity of the Derriford Appearance Scale Short-Form (DAS12): a new psychometric scale for the evaluation of patients with disfigurements and aesthetic problems of appearance.

- Proceedings of the 75th Annual Convention of the Japanese Psychological Association* 2011; 939 (in Japanese)
27. Carr T, Harris D, James C. The Derriford Appearance Scale (DAS-59): a new scale to measure individual responses to living with problems of Appearance. *Br J Health Psychol* 2000;5:201–215.
 28. Ching S, Thoma A, McCabe RE, Antony MM. Measuring outcomes in aesthetic surgery: a comprehensive review of the literature. *Plast Reconstr Surg* 2003;111:1,469–80.
 29. Nozawa K, Hayashi K, Nakakita N, Nakayama N, Ishibashi K, Imanishi N, Moss T, Harris D. Development of the Japanese version of the Derriford appearance scale (DAS59). *Jap J Plast Reconstr Surg* 2008;27:440–448 (in Japanese).
 30. The American Society for Aesthetic Plastic Surgery. Cosmetic plastic surgery statistics. 2011 <http://www.cosmeticplasticsurgerystatistics.com/statistics.html>
 31. Sarwer DB, Crerand CE. Body image and cosmetic medical treatments. *Body Image* 2004;1:99–111.
 32. Swami V Body appreciation, media influence, and weight status predict consideration of cosmetic surgery among female undergraduates. *Body Image* 2009;6:315–317.
 33. Quintard B, Lakdja F. Assessing the effect of beauty treatments on psychological distress, body image, and coping: a longitudinal study of patients undergoing surgical procedures for breast cancer. *Psychooncology* 2008;17(10):1032–8.
 34. Nozawa K, Kogoshi A, Saito Y, Aoki R. Cosmetic program improving the quality of life of hospitalized female cancer patients. *Jpn J Health Psychol* 2005–06;18(1):35–44. (in Japanese).
 35. Amiel P, Dauchy S, Bodin J, Cref C, Zenasni F, Pazent E, Teller AM, Andre F, Dipalma M. Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects. *Support Care Canc* 2009;17:839–45.

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

Masataka Sawaki · Hirofumi Mukai · Nahomi Tokudome · Takahiro Nakayama ·
Naruto Taira · Toshiro Mizuno · Yutaka Yamamoto · Akiyo Horio ·
Toru Watanabe · Yukari Uemura · Yasuo Ohashi

Received: 1 February 2011 / Accepted: 4 April 2011 / Published online: 28 April 2011
© The Japanese Breast Cancer Society 2011

Abstract

Background For targeting anti-HER-2, trastuzumab-incorporated chemotherapy is the standard for HER-2-overexpressing breast cancer in adjuvant settings. But there are few data on trastuzumab in elderly patients. We evaluated the incidence of adverse events among an elderly population of trastuzumab-treated HER-2-positive breast cancer patients in adjuvant settings.

Methods Data on 39 elderly HER-2 overexpressing breast cancer patients treated with both curative surgery and adjuvant trastuzumab were retrospectively collected from a Japanese multicenter study. The loading dose was 8 mg/kg body weight, and the maintenance dose was 6 mg/kg every 3 weeks; or the loading dose was 4 mg/kg followed by 2 mg/kg weekly as maintenance.

Results After a median follow-up of 20.0 (2.4–53.9) months, a total of 32 patients (82.1%) completed 1-year trastuzumab treatment. The median treatment duration was 12.0 months (range 2–12; mean 10.5). Adverse events occurred in 11 patients (28.2%). Four (10.2%) discontinued or interrupted treatment after experiencing toxicity. One patient died because of interstitial pneumonia. Three patients (7.7%) had congestive heart failure (CHF), one of whom had a history of angina. Three patients (7.7%) had a lower left ventricular ejection fraction (LVEF), and brain natriuretic peptide elevation was totally observed in three patients (7.7%). Three patients with lower LVEF had received chemotherapy containing doxorubicin before trastuzumab. Of the three patients, two discontinued therapy

M. Sawaki (✉)
Department of Clinical Oncology and Chemotherapy,
Nagoya University Graduate School of Medicine,
65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
e-mail: m-sawaki@med.nagoya-u.ac.jp

H. Mukai
Department of Oncology and Hematology, National Cancer
Center Hospital East, Chiba, Japan

N. Tokudome
Department of Medical Oncology,
Cancer Institute Hospital of Japanese Foundation for Cancer
Research, Tokyo, Japan

T. Nakayama
Department of Breast and Endocrine Surgery, Osaka University
Hospital, Osaka, Japan

N. Taira
Department of Breast and Endocrine Surgery, Okayama
University Hospital, Okayama, Japan

T. Mizuno
Department of Medical Oncology, Mie University Hospital, Tsu,
Japan

Y. Yamamoto
Department of Breast and Endocrine Surgery, Graduate School
of Medical Sciences, Kumamoto University, Kumamoto, Japan

A. Horio
Department of Breast Oncology, Aichi Cancer Center Hospital,
Nagoya, Japan

T. Watanabe
Department of Medicine, Hamamatsu Oncology Center,
Hamamatsu, Shizuoka, Japan

Y. Uemura · Y. Ohashi
Department of Biostatistics, School of Public Health, University
of Tokyo, Tokyo, Japan

because of CHF, but all recovered with proper medication containing a diuretic agent.

Conclusions Elderly patients tolerated trastuzumab well, although careful management is needed.

Keywords Breast cancer · HER-2/*neu* · Trastuzumab · Elderly

Introduction

The human epidermal growth factor receptor 2 (HER-2) protein is a unique and useful target for antibody therapy against breast cancers overexpressing the HER-2/*neu* gene. HER-2 is overexpressed in 15–25% of human breast cancers [1–3] and correlates with poor clinical prognosis in women with both node-positive and node-negative disease [4–6]. Overexpression of HER-2 has also been associated with potentially more aggressive tumors. As an anti-HER-2-targeting treatment, trastuzumab with chemotherapy is a standard adjuvant systemic therapy for HER-2-positive primary breast cancer [7–10]. However, trastuzumab treatment is also associated with cardiac dysfunction and congestive heart failure (CHF) [11–15]. Recently, a long-term assessment in the herceptin adjuvant (HERA) trial found that the incidence of cardiac endpoints remained low [16]. On the other hand, there have been few data on trastuzumab treatment in elderly patients because in these pivotal adjuvant clinical trials all patients had received standard chemotherapy according to the inclusion criteria. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer is well known [17, 18], so caution is necessary for elderly patients. Thus, we sought to evaluate the incidence of adverse events in an elderly population of HER-2-positive breast cancer patients treated with trastuzumab in an adjuvant setting.

Patients and methods

The data on 39 elderly (≥ 69 years) HER-2 overexpression breast cancer patients who had been treated with both curative surgery and adjuvant trastuzumab from January 2006 to February 2009 were retrospectively collected from a Japanese multicenter study. The patients did not have cardiac symptoms, uncontrolled hypertension, uncontrolled arrhythmia, or coronary artery disease in practical settings.

Adjuvant chemotherapy had been given according to the investigators' preference. Patients diagnosed with hormone-receptor-positive neoplasia were given endocrine therapy. Radiation therapy was performed in patients who had undergone breast-conserving surgery.

HER-2 status was determined by immunohistochemical (IHC) staining or amplification on fluorescence in situ hybridization (FISH). IHC scores of 3+ or FISH positive (ratio of HER-2:CEP17 ≥ 2) were regarded as positive. The loading administration dose of trastuzumab was 8 mg/kg of body weight, and the maintenance dose was 6 mg/kg every 3 weeks. Alternatively, the loading dose was 4 mg/kg followed by 2 mg/kg weekly as a maintenance dose. Cardiac function was determined by the left ventricular ejection fraction (LVEF) on echocardiography during trastuzumab treatment. The schedule of cardiac monitoring including brain natriuretic peptide (BNP) during the treatment was not defined. CHF was defined by symptoms, physical signs and objective findings; it included an LVEF drop of 10% or a drop to an absolute LVEF of 50% by the obtained echocardiogram. The severity of adverse events (AEs) was evaluated by the use of the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 3.0). Patients were monitored for clinical effects and drug-related AEs.

Results

Patients

Table 1 shows the characteristics of 39 patients. The mean age was 72.3 (69–84). As adjuvant chemotherapy, 27

Table 1 Patient characteristics ($n = 39$)

Mean age, years (range)	72.3 (69–84)
Primary stage	
I	8
II	25
III	6
Histological grade	
1	6
2	3
3	29
unknown	1
Hormone receptor	
ER (+) and/or PgR (+)	12
ER (–) and PgR (–)	27
Adjuvant chemotherapy	
Anthracyclines and taxanes	6
Anthracyclines, no taxanes	19
Taxanes, no anthracyclines	1
CMF	1
No cytotoxic chemotherapy	12
Adjuvant hormone therapy	
Aromatase inhibitor	11
Tamoxifen	1
No	27

patients (69.2%) had sequential chemotherapy. Of those, 25 (92.6%) had an anthracycline-containing regimen. For six of these patients, this consisted of FEC/FAC: fluorouracil 500 mg/m², epirubicin 75–100 mg/m², doxorubicin 40–60 mg/m², and cyclophosphamide 500 mg/m² every 3 weeks for more than four cycles; or AC: doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² every 3 weeks for four cycles and taxane (paclitaxel or docetaxel). In 19 patients, the anthracycline-containing regimens included the following. One patient had CMF (cyclophosphamide 100 mg orally on days 1 to 14, methotrexate 40 mg/m² on days 1 and 8 intravenously, and fluorouracil 600 mg/m² intravenously on days 1 and 8, every 4 weeks for six cycles); one had TC (docetaxel 60 mg/m² and cyclophosphamide 600 mg/m² every 3 weeks for four cycles; and 12 patients (30.8%) had trastuzumab therapy without chemotherapy.

Safety and tolerability

After a median follow-up time of 20.0 (2.4–53.9) months, a total of 32 patients (82.1%) had completed receiving trastuzumab for 1 year. The median duration of treatment was 12.0 months (range, 2 to 12 months; mean, 10.5 months). Two patients (5.1%) are continuing treatment because they have not completed 1 year; three patients (7.7%) discontinued treatment because of toxicity; one patient (2.6%) had interrupted treatment because of toxicity but was reintroduced after recovery; one patient

(2.6%) discontinued after relapse. Adverse events are shown in Tables 2 and 3. Adverse events occurred in 11 patients (28.2 %). One patient died after toxicity led to interstitial pneumonia (IP). She had been undergoing hormone therapy (anastrozole) with trastuzumab after irradiation for the breast. In the CT scan the density of pneumonia was detected almost in accordance with the irradiation area. From the autopsy, it was diagnosed as IP that had been induced by neither infection nor carcinomatous lymphangiosis. The cause of IP was not specified and not significantly related to trastuzumab, although it should not always be denied directly. Three patients (7.7%) had CHF, 2 of whom complained of systemic edema, and 3 had dyspnea. One of these three CHF patients had a history of angina. In particular, regarding cardiotoxicity examinations, three patients (7.7%) had lower LVEF, of whom two also had elevated BNP. BNP elevation was totally observed in three patients (7.7%). Three patients with lower LVEF had been receiving chemotherapy containing doxorubicin immediately prior to the initiation of trastuzumab treatment. Two of the three patients with lower LVEF were discontinued because of CHF, but all recovered with proper medication containing a diuretic agent.

We here present a case of CHF in a 70-year-old female diagnosed with left breast cancer: T1c, N1, M0, stage IIA. Her pathology was estrogen-receptor-positive, progesterone-receptor-negative, and HER-2-positive (3+; IHC). She had received FAC neoadjuvant chemotherapy (the doxorubicin cumulative dose was 260 mg/m²), followed by 12 courses of weekly paclitaxel. The points of EF and BNP before chemotherapy were 64% and 12.1 pg/ml, respectively. The cardiothoracic ratio (CTR) was 51.3% (Fig. 1a). After she completed chemotherapy, she underwent surgery, after which she received tamoxifen and irradiation for the chest wall, supraclaviculares, and parasternal lymph nodes. After completion of irradiation, trastuzumab treatment was begun. At this time, the point of EF was 73%. The loading administration dose of trastuzumab was 8 mg/kg body weight, and the maintenance dose was 6 mg/kg every 3 weeks. After three cycles of trastuzumab, she experienced dyspnea and leg edema. The point of EF was decreased from 73 to 53%, BNP was

Table 2 Adverse events (*n* = 39)

Events	Grade (G); patients (%)
Acute infusion reaction	G1; 6 (15.4)
Edema	G1; 1, G2; 1 (5.1)
Dyspnea	G1; 1, G3; 2 (7.7)
Rash	G1; 1, G2; 1 (5.1)
Nail change	G1; 2 (5.1)
Interstitial pneumonia	G5; 1 (2.6)
Left ventricular systolic dysfunction	G1; 1, G3; 2 (7.7)
Elevated brain natriuretic peptide	3 (7.7)

Table 3 Adverse events (grade 2–5)

Age	Chemotherapy	Trastuzumab treatment	Cardio-toxicity	Ejection fraction (%)	Pulmonary-toxicity	Duration of trastuzumab (months)
76	None	Tri-weekly	None	62–67	Interstitial pneumonia	2
77	None	Tri-weekly	CHF ^a ; G3	69–68	None	5
71	CAF (ADM 300 mg/m ²)	Tri-weekly	CHF ^a ; G3	70–49	None	8
70	CAF (ADM 260 mg/m ²), weekly PTX	Tri-weekly	CHF ^a ; G2	73–53	None	2

^a Congestive heart failure




Fig. 1 **a** The points of EF and BNP before chemotherapy were 64% and 12.1 pg/ml, respectively. The cardiothoracic ratio (CTR) was 51.3%. **b** After three cycles of trastuzumab, our patient had dyspnea and leg edema. The point of EF was decreased from 73 to 53%, BNP was elevated from 12.1 to 40.7 pg/ml, and CTR was 60.5%. **c** After 1 week, her heart function had recovered, the point of CTR had decreased from 60.5 to 54.8%, and BNP had also decreased from 40.7 to 9.3 pg/ml

elevated from 12.1 to 40.7 pg/ml, and the CTR was 60.5% (Fig. 1b). She was diagnosed with heart failure (grade 2) by a cardiologist and given a diuretic agent, furosemide

(80 mg/day). After 1 week, her heart function had recovered, the point of CTR had decreased from 60.5 to 54.8%, and the BNP had also decreased from 40.7 to 9.3 pg/ml (Fig. 1c). Trastuzumab was reintroduced after LVEF recovery without any other problems.

Outcomes

Of the 39 patients, 2 (5.1%) died; 1 of these deaths was caused by IP, while the other was non-breast cancer-specific deaths. Thirty-six patients (92.3%) were free of relapse, and one had distant metastasis. All patients who completed 1 year of treatment have experienced no more cardiotoxicity or other adverse events.

Discussion

Treatment of breast cancer with trastuzumab is complicated by cardiotoxicity [19]. Cardiac safety in major adjuvant trials is shown in Table 4. The incidence of cardiac endpoints after a long-term assessment in the HERA trial was recently reported. The incidence of discontinuation of trastuzumab because of cardiac disorders was low (5.1%), that of severe CHF was 0.8%, and that of confirmed significant LVEF decreases was 3.6% [16]. In the other pivotal studies [10, 20, 21], the cardiac event rate was highest in the anthracycline-containing trastuzumab patients (1.9–3.8%) and lowest in patients who had received the regimen of docetaxel, carboplatin, and trastuzumab (TCH) (0.4%). But there are not enough data available on trastuzumab treatment in elderly patients. Thus, it was necessary to evaluate the incidence of adverse events, in particular cardiotoxicity, in an elderly population of HER-2-positive breast cancer patients.

Although the patient population in this study was small, we presented safety data on trastuzumab for elderly breast cancer patients. Overall, the incidence of adverse events was low. Only four patients (10.2%) discontinued treatment because of toxicity. Three patients (7.7%) had CHF, but all recovered with proper medication containing a diuretic agent. As for the treatment for heart failure (HF) caused by trastuzumab-induced cardiotoxicity, in most patients it is reversible [19, 22–25]. LVEF improves after trastuzumab withdrawal and with, or sometimes without, the initiation of HF therapy [19]. Although the identification of patients at risk for trastuzumab-induced cardiotoxicity and the prediction of LVEF recovery have never been investigated, recently troponin 1 was found to be a predictive risk factor for cardiotoxicity, and patients with troponin 1 elevation were unlikely to recover from cardiac dysfunction despite HF therapy [19].

Table 4 Cardiac safety in the four major adjuvant trials

Trial	ARM	Baseline LVEF (%)	CHF ^a (%)	Cardiac death (n)
HERA [16]	H 1 year	≥55	0.6	0
	Nil		0	1
NSABP B-31 [21]	AC → P	≥50	0.9	1
	AC → PH		3.8	0
N9831 [20]	AC → P	≥50	0.2	1
	AC → PH		2.5	1
BCIRG 006 [10]	AC → D	≥50	0.4	0
	AC → DH		1.9	0
	D Carbo H		0.4	0

^a Congestive heart failure

Trastuzumab is indicated for HER-2-positive patients according to the ASCO/CAP guideline [26]. Especially for elderly patients, there is clinical significance to demonstrating the benefit of trastuzumab without toxicity induced by chemotherapy. We have thus been investigating clinical positioning between trastuzumab monotherapy and a combination of trastuzumab and chemotherapy based on a randomized controlled trial in women aged over 70 years with HER-2-positive primary breast cancer [27]. Our hypothesis is that the trastuzumab monotherapy group is not inferior to the trastuzumab and chemotherapy group in disease-free survival, and is superior in safety and health-related quality of life; these are registered as protocol ID: UMIN000002349 for the University Hospital Medical Information Network (UMIN) and protocol ID: NCT01104935 for ClinicalTrials.gov. To prepare this multicenter study, we collected trastuzumab treatment data to ascertain the feasibility of this treatment for elderly patients.

In summary, elderly patients tolerated trastuzumab well, although careful management is needed. Prospective data on a larger number of elderly patients are needed in order to confirm the safety of trastuzumab treatment in elderly patients.

Acknowledgments This study was presented in part at the 18th annual meeting of the Japanese Breast Cancer Society on 24–25 June 2010 in Sapporo, Japan. This study was conducted by the executive committee of the National Surgical Adjuvant Study of Breast Cancer 07, which was supported by the Comprehensive Support Project for Oncology Research of the Public Health Research Foundation, Japan. We would also like to thank Mrs. Naomi Ushiyama for this publication.

Conflict of interest The authors state that they have no conflict of interest.

References

- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987;235:177–82.
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*. 1989;244:707–12.
- Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) breast cancer study group. *J Clin Oncol*. 1992;10:1049–56.
- Seshadri R, Fircgair FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian breast cancer study group. *J Clin Oncol*. 1993;11:1936–42.
- Ravdin PM, Channess GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers—a review. *Gene*. 1995;159:19–27.
- Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. *J Clin Oncol*. 1997;15:2894–904.
- Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*. 2005;353:1673–84.
- Piccant-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*. 2005;353:1659–72.
- Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *Lancet*. 2007;369:29–36.
- Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: Bcirg 006 study. *Cancer Res*. 2009;69:500S.
- Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. *Oncology*. 2001;61(Suppl 2):58–66.
- Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. *Breast*. 2004;13:173–83.
- Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse

- effects in the herceptin adjuvant trial. *J Clin Oncol.* 2007;25:3859–65.
14. Ishihara M, Mukai H, Nagai S, Mukohara T. Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. *Int J Clin Oncol.* 2009;14:431–5.
 15. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. *Ann Oncol.* 2010;21:2153–60.
 16. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. *J Clin Oncol.* 2010;28:3422–8.
 17. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. *J Clin Oncol.* 2007;25:3808–15.
 18. Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. *Cancer.* 2009;115:5296–308.
 19. Cardinale D, Colombo A, Torrìs R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin i evaluation. *J Clin Oncol.* 2010;28:3910–6.
 20. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. *J Clin Oncol.* 2008;26:1231–8.
 21. Rastogi P, Jeong J, Geyer CE, Costantino JP, Romond EH, Ewer MS, et al. Five year update of cardiac dysfunction on nsabp B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab(H). *J Clin Oncol.* 2007;25:suppl;abstr LBA513.
 22. Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? *J Clin Oncol.* 2010;28:3407–10.
 23. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. *J Clin Oncol.* 2007;25:3525–33.
 24. Ewer MS. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol.* 2005;23:7820–6.
 25. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience. *J Clin Oncol.* 2006;24:4107–15.
 26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol.* 2007;25:118–45.
 27. Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2 positive elderly breast cancer patients: N-SAS BC 07 (RESPECT study). *Jpn J Clin Oncol.* doi:10.1093/jjco/HYR011.

がん患者コホート研究

— 予後改善へのエビデンス

Prospective studies of cancer survivorship : Prognosis and QOL



溝田友里 (写真左) 山本精一郎 (写真右)

Yuri MIZOTA^{1,2} and Seiichiro YAMAMOTO¹

国立がん研究センターがん対策情報センター¹, 同がん予防・検診研究センター²

◎診断・治療技術の向上や人口構成の変化、生活習慣の変化など、さまざまな要因を背景に、がんサバイバー、すなわちがんを抱えながら生活する人が増えている。患者の立場からは再発の不安も大きく、日常生活のなかでも再発を防ぐために努力をしたいという思いは強いが、再発や死亡といった予後に関連する生活習慣を明らかにするエビデンスレベルの高い疫学研究が、日本のみならず世界的にも不足している。そのため、再発予防のためのがん患者への指針については明確な推奨がなく、「がん患者を含めたすべての人が、がん予防のための推奨事項に従う」との記載にとどまっている。そのような現状を背景に近年、乳がんを中心に、生活習慣と予後との関連を調べる大規模前向き疫学研究が開始され、患者の予後向上と療養生活の質の向上につながることを期待されている。本稿では、国内外の乳がん大規模疫学研究の進展について報告するとともに、著者が開始した大規模前向き乳がんコホート研究である Rainbow of KIBOU Study について紹介する。



Key word : がん患者、乳がんコホート、再発、予後、生活習慣、ROK Study

がん患者の再発予防のための生活習慣

がんの発症にかかわるリスクファクターについては、本特集でこれまで述べられてきたように、JPHC Study (Japan Public Health Center-based Prospective Study) をはじめとするさまざまな疫学研究の蓄積により、生活習慣とがんの発症に関して多くのエビデンスが構築されている。しかし、がんの再発については、再発や死亡といった予後に関連する生活習慣を明らかにするエビデンスレベルの高い疫学研究が、日本のみならず世界的にも不足している。

そのため生活習慣を中心に、がんの発症や再発との関連を検討した研究のシステマティックレビューを行い作成されたアメリカがん協会 (American Cancer Society : ACS) の “Guidelines on Nutrition and Physical Activity for Cancer Prevention”¹⁾ や、世界がん研究基金/アメリカがん研究財団 (World Cancer Research Fund : WCRF/American Institute for Cancer

Research : AIC) の “Food, nutrition, physical activity and the prevention of cancer : a global perspective”²⁾ でも、予後(再発、死亡)をエンドポイントとしたエビデンスレベルの高い研究がきわめて少ないため、再発予防のためのがん患者への指針については明確な推奨がなく、「がん患者を含めたすべての人が、がん予防のための推奨事項に従う」との記載にとどまっている。



がん患者を対象とする 大規模前向き疫学研究

診断・治療技術の向上や人口構成の変化、生活習慣の変化など、さまざまな要因を背景に、がんサバイバー、すなわちがんを抱えながら生活する人が増えている。効果のある治療法が存在しても、患者の立場からは再発の不安も大きく、日常生活のなかでも再発を防ぐために努力をしたいという思いが強い。とくに食事や運動、病気との付き合い方など、自分でも変更が可能な生活習慣の

なかで、再発予防効果をもつものを取り入れたいという期待が大きい。

しかし前述のとおり、治療以外の要因と予後との関連を調べたエビデンスレベルの高い研究は国内外ともきわめて少なく、どのような療養生活を送ればよいか明らかになっていない。エビデンスがないにもかかわらず、“乳がんと牛乳”といった再発予防に関する書籍は世界中でベストセラーとなり、患者は代替療法への高額な出費や、食事や生活面のさまざまな自主規制などを行っている。著者らが国立がん研究センター中央病院の乳がん患者を対象に実施した調査でも、患者の多くが高額な代替療法の利用や自己流の食事制限を行っていることが明らかになり、再発を防ぐための療養情報に対する関心の高さとともに、そのような行動がむしろQOLを低めている可能性があることが明らかになった。これらのことから患者側に立った、実践するに足る、効果のある生活習慣などを明らかにすることは、患者の予後向上およびQOL向上に大きく寄与すると考えられる。

このようなニーズを背景として、がん患者における生活習慣と予後との関連を明らかにしようとする大規模前向き疫学研究が、国内外ともようやく開始されはじめた。

現時点で、前述のWCRF/AICRやアメリカ国立がん研究所(National Cancer Institute: NCI)のPhysician Data Query®(PDQ®)³⁾によるシステムティックレビューで引用されている、曝露要因、予後(再発、死亡)をがんと生活習慣のエンドポイントとした大規模前向き疫学研究には、Women's Intervention Nutrition Study(WINS Study)、Women's Healthy Eating and Living randomized trial(WHEL Study)、Women's Intervention Nutrition Study(LACE Study)、Shanghai Breast Cancer Study(Shanghai BCSS)などがあり、そのほとんどは乳がん患者が対象である。

日本の大規模前向き疫学研究では、愛知県がんセンターのHospital-based Epidemiologic Research Program at Aichi Cancer Center(HERPACC)のデータを用いた全がんを対象とする患者コホート研究や、著者らが開始した乳がん患者コホート研究であるRainbow of KIBOU

Study(ROK Study)などがある。

以下では、がん患者の生活習慣と予後との関連を調べる大規模前向き疫学研究のなかで、他のがん種に先行して研究が進められている乳がんに関して、国内外の研究のこれまでの進展を紹介する。

乳がん患者を対象とする 大規模前向き疫学研究

乳がんは世界的にみても女性にもっとも多いがんであり、国際がん研究機関(International Agency for Research on Cancer: IARC)の推計によると、世界で138万人が2008年に新たに乳がん罹患し⁴⁾、日本でも2006年の推計では新たに53,783人が罹患している⁵⁾。一方で、乳がんは比較的予後が良好なため、サバイバーが特に多いがんのひとつである。そのため、伝統的に患者を対象とする研究が、他がんに先行して多く行われてきた。しかし、先行して研究が進められている乳がんであっても、食事や身体活動などの生活習慣や心理社会的要因、代替療法利用などと予後との関連を調べるエビデンスレベルの高い研究は開始されたばかりである。

最近の研究結果から、乳がん診断時や乳がん診断後の肥満、身体活動などについては、予後との関連が示されつつあるが、ほとんどの要因についてはまだ明らかになっていない^{1-3,6-13)}。

近年開始された、乳がん患者の生活習慣と予後との関連を調べる大規模前向き疫学研究のうち、主要なものを表1に示した。これらの研究によりアルコールや脂肪、ビタミンD、イソフラボンの摂取などの食事や、喫煙、肥満、身体活動、代替療法利用などをはじめとするさまざまな要因と乳がんの予後との関連の検討が行われつつあり、今後、がんの再発予防に寄与する要因が明らかになることが期待されている。

Rainbow of KIBOU Study (ROK Study)

以下では、日本における乳がん患者の大規模前向きコホート研究として、著者らが進めているRainbow of KIBOU Study(ROK Study)について、研究デザインと進捗を紹介する。

表 1 習慣や環境要因と予後との関連を調べる大規模前向き疫学研究

Study name	Setting	Approximate number of enrolled	
		Current*	Projected
ランダム化比較試験 Women's Intervention Nutrition Study (WINS) Women's Healthy Eating and Living Study (WHEL Study)	U. S. (multicenter)	2,437	2,437
	U. S. (multicenter)	3,088	3,088
前向きコホート研究 Health, Eating, Activity and Lifestyle Study (HEAL Study) Life After Cancer Epidemiology (LACE) Study Shanghai Breast Cancer Survivors Study (Shanghai BCSS) DietCompLyf Study Pathways Rainbow of KIBOU Study (ROK Study)	Puget Sound, Los Angeles County, New Mexico	1,182	1,182
	Kaiser Permanente Northern California, Utah, other	2,321	2,321
	Shanghai	5,033	~5,000
	U. K. (multicenter)	~1,560	~3,000
	Kaiser Permanente Northern California	~2,279	>4,000
	Japan (multicenter)	~1,851	7,100

* : 著者ら調べ(2012年3月5日, PubMed).

(文献⁹⁾をもとに著者らが加筆)

1. 研究目的

ROK Studyの目的は、乳がん患者を対象とする大規模前向きコホート研究を行うことにより、さまざまな要因(生活習慣、心理社会的要因、代替療法など)が予後(再発、死亡など)や罹患後の療養生活の質(QOL)に与える影響を、疫学的に調べることである。

2. 研究デザインと対象(表2)

ROK Studyは多施設臨床試験の共同研究として、臨床試験参加者を対象に実施している3つのコホート(表2の①~③)と、国立がん研究センター中央病院で手術を受ける全乳がん患者を対象とする1つのコホート(表2の④)、および中国・四国地域の乳がん登録の共同研究として、乳がん登録参加施設の全乳がん患者を対象とする1つのコホート(表2の⑤)の計5つのコホートからなっている。

コホート05、コホート06、コホート07は財団法人パブリックヘルスリサーチセンターがん臨床研究支援事業(CSPOR)が実施主体となる臨床試験との共同研究であり、各コホートとも日本全国から100前後の施設が参加している。予定登録数はそれぞれ2,500人、1,200人、200人である。

コホートNCCは、臨床試験や乳がん登録とは独立して、国立がん研究センター中央病院の日常診療のなかで全乳がん患者を対象に実施するコ

ホート研究である。質問票に加え試料(がん組織、血液)の採取も行うため、通常のコホート研究と同様に生活習慣などと予後との関連の検討が行えると同時に、血中バイオマーカーや遺伝子多型と予後との関連の検討も可能となる。予定登録数は1,200人である。

さらに2012年夏より、NPO法人瀬戸内乳癌事業包括的支援機構の瀬戸内乳がん登録の共同研究として、コホート瀬戸内を開始する予定である。瀬戸内乳がん登録は、中国・四国地方において多施設乳がん登録システムを構築し、大規模データベースの解析による疫学研究を実施することを目的としており、予定登録数は2,000人である。

全体として、5つのコホートで目標登録数は計7,100人となる。

3. 曝露要因の収集

図1にROK Studyの概略、図2に収集するデータとタイミングを示した。

無記名自記式の質問票から生活習慣(食事、身体活動など)、心理社会的要因、代替療法の利用、痛みと支持療法、QOL(全般的QOL、FACT-B、FACT-ES)などについての情報を収集する。食事および身体活動状況については、JPHC Studyと同様のものを用いている。また、本研究では予後への影響に加え、患者の療養生活の質の向上という観点からも心理社会的要因に注目し、患者の